Lupin is currently trading at Rs. 1452.00, up by 11.85 points or 0.82% from its previous closing of Rs. 1440.15 on the BSE.
The scrip opened at Rs. 1449.00 and has touched a high and low of Rs. 1457.00 and Rs. 1445.75 respectively. So far 13,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1874.30 on 14-Mar-2016 and a 52 week low of Rs. 1294.05 on 29-Mar-2016.
Last one week high and low of the scrip stood at Rs. 1478.95 and Rs. 1425.00 respectively. The current market cap of the company is Rs. 65,496.00 crore.
The promoters holding in the company stood at 46.71%, while Institutions and Non-Institutions held 41.46% and 11.83% respectively.
Lupin has received final US Food and Drug Administration (USFDA) approval for ANDA Moxifloxacin Hydrochloride Tablets, 400 mg, generic of Avlox Tablets of Bayer Healthcare Pharmaceuticals, Inc.
The company has recently received final approval for its Triamcinolone Acetonide Cream USP, 0.025%, 0.1% and 0.5% from the USFDA to market a generic equivalent of Mylan Pharmaceuticals Inc.’s Triamcinolone Acetonide Cream, 0.025% and 0.1%.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.